Proaxsis

ProAxsis Limited is a commercial-stage global diagnostics company, based in Northern Ireland, and with a rapidly growing client list of pharmaceutical companies and academic laboratories. The company promotes a range of assay kits designed for the specific measurement of active protease biomarkers of disease. Our easy-to-use tests incorporate patented “ProteaseTags®”; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. This technology has been translated in to a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha. Aside from the provision of assays, ProAxsis is able to offer sample analysis at its purpose-built laboratory facility in Belfast, and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.